BBA
DYN icon

Baker Bros. Advisors’s Dyne Therapeutics DYN Stock Holding History

Baker Bros. Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.7M Hold
813,449
– – 0.08% 62
2025
Q4 		$15.9M Buy
+813,449
New +$15.4M 0.09% 63
2025
Q2 		– Sell
-672,096
Closed -$7.03M – 92
2025
Q1 		$7.03M Hold
672,096
– – 0.08% 53
2024
Q4 		$15.8M Hold
672,096
– – 0.17% 44
2024
Q3 		$24.1M Hold
672,096
– – 0.25% 38
2024
Q2 		$23.7M Buy
672,096
+387,096
+136% +$11.2M 0.3% 38
2024
Q1 		$8.09M Buy
+285,000
New +$6.45M 0.1% 54

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Baker Bros. Advisors's DYN Position: Q1 2026 in Review

Baker Bros. Advisors held its Dyne Therapeutics (DYN) position steady in Q1 2026 at 813,449 shares worth $14.7M. The position accounts for 0.08% of the portfolio, ranked #62.

Baker Bros. Advisors first reported a position in DYN in Q1 2024 and has held it in 7 quarters since. The position peaked at $24.1M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Baker Bros. Advisors held 813,449 shares of Dyne Therapeutics worth $14.7M as of Q1 2026.
  • Baker Bros. Advisors left its Dyne Therapeutics share count unchanged in Q1 2026.
  • Dyne Therapeutics made up 0.08% of Baker Bros. Advisors's portfolio in Q1 2026, its #62 holding.
  • Baker Bros. Advisors first reported a position in Dyne Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Baker Bros. Advisors's Dyne Therapeutics position peaked at $24.1M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.